Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini reported an exercise-and-sell transaction in Class A Ordinary Shares. On May 1, 2026, he exercised options to acquire 58,424 shares at $10.36 per share and then sold the same number of shares in two open-market transactions at weighted average prices of $53.52 and $54.04. The sales were executed through a broker under a pre-arranged Rule 10b5-1 trading plan. Following the exercise, 29,670 share options remained outstanding and are fully vested, with an expiration date in February 2028.

Insights

Insider transactions analyst

Kiniksa's CMO executed a routine option exercise-and-sell under a Rule 10b5-1 plan.

Chief Medical Officer John F. Paolini exercised options for 58,424 Class A Ordinary Shares at $10.36 per share and sold the same number of shares in two open-market trades at weighted average prices of $53.52 and $54.04 on May 1, 2026.

This pattern—exercise followed by immediate sale—typically reflects liquidity from equity compensation rather than a directional bet. The filing notes the trades were made under a Rule 10b5-1 plan executed on November 18, 2025, indicating the timing was pre-planned, which further reduces signaling value.

After the transaction, 29,670 options remained outstanding, fully vested, and expiring on February 29, 2028. Future company filings may show how Paolini manages these remaining options over time.

Insider Trade Summary 10b5-1

Net Seller: 58,424 shares ($3,137,823)

Net Sell 4 txns

Insider Paolini John F.

Role CHIEF MEDICAL OFFICER

Sold 58,424 shs ($3.14M)

Type	Security	Shares	Price	Value
Exercise	Share Option	58,424	$0.00	--
Exercise	Class A Ordinary Share	58,424	$10.36	$605K
Sale	Class A Ordinary Share	37,327	$53.52	$2.00M
Sale	Class A Ordinary Share	21,097	$54.04	$1.14M

Holdings After Transaction: Share Option — 29,670 shares (Direct, null); Class A Ordinary Share — 124,047 shares (Direct, null)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $52.765 and $53.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $53.765 and $54.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable.

Key Figures

Shares sold (block 1): 21,097 shares at $54.04 Shares sold (block 2): 37,327 shares at $53.52 Options exercised: 58,424 shares at $10.36 +1 more

4 metrics

Shares sold (block 1) 21,097 shares at $54.04 Open-market sale of Class A Ordinary Shares on May 1, 2026

Shares sold (block 2) 37,327 shares at $53.52 Open-market sale of Class A Ordinary Shares on May 1, 2026

Options exercised 58,424 shares at $10.36 Exercise of share options into Class A Ordinary Shares on May 1, 2026

Remaining options 29,670 share options Fully vested options outstanding after exercise, expiring February 29, 2028

Key Terms

Rule 10b5-1 plan, weighted average sales price, Class A Ordinary Share, Share Option, +1 more

5 terms

Rule 10b5-1 plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sales price financial

"The price reported in this column reflects a weighted average sales price"

Class A Ordinary Share financial

"security_title: Class A Ordinary Share"

A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.

Share Option financial

"security_title: Share Option"

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paolini John F.

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	05/01/2026		M(1)		58,424	A	$10.36	124,047	D
Class A Ordinary Share	05/01/2026		S(1)		37,327	D	$53.52(2)	86,720	D
Class A Ordinary Share	05/01/2026		S(1)		21,097	D	$54.04(3)	65,623	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$10.36	05/01/2026		M(1)			58,424	(4)	02/29/2028	Class A Ordinary Share	58,424	$0	29,670	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $52.765 and $53.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $53.765 and $54.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Kiniksa (KNSA) report for its Chief Medical Officer?

Kiniksa reported that Chief Medical Officer John F. Paolini exercised options for 58,424 Class A Ordinary Shares and sold the same 58,424 shares in open-market trades. The exercise price was $10.36 per share, with sales at weighted average prices of $53.52 and $54.04.

Were the Kiniksa (KNSA) insider share sales by John Paolini pre-planned under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan executed by John F. Paolini on November 18, 2025. Such pre-arranged plans schedule trades in advance, reducing the informational significance of the exact sale timing for investors.

What prices were involved in John Paolini’s Kiniksa (KNSA) share sales and option exercise?

John Paolini exercised options at $10.36 per share for 58,424 Kiniksa Class A Ordinary Shares. He then sold 21,097 shares at a weighted average price of $54.04 and 37,327 shares at a weighted average price of $53.52 in broker-executed trades.

How many Kiniksa (KNSA) share options does John Paolini still hold after this Form 4 filing?

After exercising 58,424 options, the Form 4 shows John Paolini with 29,670 remaining share options. These options are fully vested and exercisable, with an expiration date of February 29, 2028, providing potential future equity exposure if exercised.

What type of securities did Kiniksa (KNSA) CMO John Paolini transact in this Form 4?

The transactions involved Kiniksa Class A Ordinary Shares and related share options. Paolini exercised share options to obtain 58,424 Class A Ordinary Shares, then sold those shares in open-market brokered trades, while retaining 29,670 fully vested share options expiring in 2028.